Aβ Dynamics in LLMD (NCT05004987) | Clinical Trial Compass
RecruitingPhase 4
Aβ Dynamics in LLMD
United States60 participantsStarted 2022-02-04
Plain-language summary
This study will examine the biological factors that may modulate the relationship between depression and the development of Alzheimer's disease (AD). Since the direction of causation between depression and the biological factors associated with AD is unknown, the only way to understand cause and associated risk is to treat the depressive symptoms and examine the effects on AD biomarkers. The study involves an FDA-approved treatment for major depressive disorder. It will compare the SSRI antidepressant escitalopram with placebo. The hypothesis is that a reduction in depressive symptoms will be associated with a normalization of CSF AD biomarkers as well as peripheral inflammatory markers. This research would contribute to fundamental knowledge about potentially modifiable risks of Alzheimer's disease (AD).
Who can participate
Age range60 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Male and female subjects, age 60+ years inclusive, at the time of signing the informed consent.
✓. Meeting Structured Clinical Interview (SCID-5-RV) for DSM-5 criteria for Major depressive disorder.
✓. Have results of a physical examination, neurological examination, vitals, and EKG within normal limits at screening.
✓. Cognitively unimpaired at screening visit as defined by Mini-Mental State Examination (MMSE) \>27.
✓. Clinical Dementia Rating Scale (CDR) Global of 0\*.
✓. A score of 85 or greater on the RBANS delayed memory index score.
✓. Fluent in English, because some of the instruments used in this study have not been translated and validated in other languages, and are able to read at a 6th grade level or equivalent, as determined by the PI.
Exclusion criteria
✕
What they're measuring
1
Change in Cerebrospinal Fluid (CSF) Aβ40 Biomarker Levels
Timeframe: Baseline, Week 8
2
Change in Cerebrospinal Fluid (CSF) Aβ42 Biomarker Levels
Timeframe: Baseline, Week 8
3
Change in Vascular Dysfunction (VD) Biomarker Levels
Timeframe: Baseline, Week 8
4
Change in Scores on Montgomery-Asberg Depression Ration Scale (MADRS)
. History of brain tumor, MRI evidence of brain damage or brain disease including significant trauma, hydrocephalus, seizures, or confluent (or more extensive) white matter hyperintensities.
✕. Mental retardation, or other serious neurological disorder (e.g. Parkinson's disease or other movement disorders).
✕. Subjects with a Fazekas scale \>2.
✕. Significant history of alcoholism or drug abuse in the past 2 years. Fulfilling SCID-5-RV/DSM-5 criteria for current or past diagnosis of any psychiatric disorder (e.g., schizophrenia, bipolar disorder, or any psychotic disorder) other than recurrent MDD or anxiety disorders (e.g., panic disorder, agoraphobia, etc.).
✕. A current significant risk for suicidality based on the Columbia-Suicide-Severity Rating Scale (C-SSRS).
✕. Insulin dependent diabetes.
✕. Evidence of clinically relevant or unstable cardiac, pulmonary, endocrine or hematological conditions.
✕. Any prosthetic devices (e.g., pacemaker or surgical clips) that constitutes a hazard for MRI imaging.